Skip to main content
Signal8
Launch Terminal

Aura Biosciences, Inc. (AURA)

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

NASDAQ:AURAHealthcare
-2.46%$6.14
AH$6.14+0.00%vs close
Mkt Cap$636.75M
Float92.38M
O/S103.7M
Vol
$ Vol
RVOL
Inst Own92.2%
SI11.8%
Earnings
Dilution
Aura Biosciences, Inc. logoNASDAQ:AURA$6.14-2.46%
Phase Distribution
10 lead-sponsored trials·6 active·3 completed
Phase 11
Phase 1/21
Phase 22
Phase 31
Not applicable5
Status Overview
Recruiting2
Active, not recruiting4
Completed3
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Active, not recruiting

    A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

    Bel-sar

    Choroidal Melanoma, Indeterminate Lesions +2

    Enrollment
    108
    Start
    Dec 2023
    Primary Completion
    Nov 2027est.
    Completion
    Aug 2028est.
    NCT06007690
  • Phase 2
    Completed

    Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

    AU-011

    Uveal Melanoma, Ocular Melanoma +1

    Enrollment
    22
    Start
    Aug 2020
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT04417530
  • Phase 2
    Recruiting

    Suprachoroidal Administration in Subjects With Metastases to the Choroid

    AU-011

    Eye Cancer, Primary Cancer

    Enrollment
    24
    Start
    Dec 2024
    Primary Completion
    Nov 2026est.
    Completion
    Oct 2027est.
    NCT06643884
  • Phase 1/2
    Completed

    Study in Subjects With Small Primary Choroidal Melanoma

    Light-activated AU-011

    Uveal Melanoma, Ocular Melanoma +1

    Enrollment
    57
    Start
    Feb 2017
    Primary Completion
    Jan 2021
    Completion
    Jan 2021
    NCT03052127
  • Phase 1
    Active, not recruiting

    A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

    AU-011

    Non-muscle-invasive Bladder Cancer, NMIBC +4

    Enrollment
    55
    Start
    Sep 2022
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2027est.
    NCT05483868
  • Observational
    Active, not recruiting

    A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

    -

    Choroidal Melanoma, Indeterminate Lesions of Eye

    Enrollment
    63
    Start
    Mar 2019
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2029est.
    NCT03941379
  • Observational
    Terminated

    Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

    AU-011

    Choroidal Melanoma, Indeterminate Lesions

    Enrollment
    2
    Start
    Apr 2022
    Primary Completion
    Feb 2023
    Completion
    Apr 2023
    NCT05266430
  • Observational
    Completed

    Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study

    -

    Mood, Depression Disorders +6

    Enrollment
    912
    Start
    Nov 2024
    Primary Completion
    Apr 2026
    Completion
    Apr 2026
    NCT06664944
  • Observational
    Enrolling by invitation

    A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

    Observational

    Choroidal Melanoma, Indeterminate Lesions

    Enrollment
    100
    Start
    Mar 2026
    Primary Completion
    Aug 2033est.
    Completion
    Aug 2033est.
    NCT07338968
  • Observational
    Active, not recruiting

    Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

    Non-interventional, digital, patient-reported, study

    Choroidal Melanoma, Indeterminate Lesions +2

    Enrollment
    15
    Start
    Nov 2025
    Primary Completion
    Aug 2028est.
    Completion
    Aug 2028est.
    NCT07421739
Search ClinicalTrials.gov for “Aura Biosciences”